Impact of GLP-1 Drugs on Digestion and Energy GLP-1 medications slow gastric emptying, meaning food stays in the stomach longer
Zhao W, Wang J, Deng R, Wang X (2008) Scale-up fermentation of recombinant Candida rugosa lipase expressed in Pichia pastoris using the GAP promoter
The compound was never approved as a pharmaceutical treatment for obesity because the Phase 2 clinical trial results, while showing safety and modest efficacy, did not meet the threshold for drug registration
Disadvantages: Requires daily dosing and strict timing with meals for optimal absorption
Improved Overall Well-being Users report better mood, energy, and vitality
Rare variants in genes linked to appetite control and hypothalamic development in early-onset severe obesity